ExpressPoints: EGFR-Mutant Advanced NSCLC: Global Insights on Testing and Treatment Planning

Download this living summary slideset of key takeaways from a live CCO Webinar featuring the latest clinical data informing optimal treatment of patients with EGFR-mutant advanced NSCLC, including guidance on testing for EGFR mutations and new data from ASCO 2021.
Edward S. Kim, MD, FACP, FASCO
Tetsuya Mitsudomi, MD
Luis Paz-Ares, MD, PhD
person default
Daniel SW Tan, BSc, MBBS, MRCP, PhD
Format: Microsoft PowerPoint (.ppt)
File Size: 2.05 MB
Released: June 23, 2021

Acknowledgements

Provided by Clinical Care Options, LLC.

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
AstraZeneca

Related Content

Update of ATEZO-BRAIN trial evaluating atezolizumab plus chemotherapy in patients with advanced nonsquamous NSCLC with untreated brain metastases, presented at ASCO 2022 and reported by Clinical Care Options (CCO)

Released: June 16, 2022

Phase I CHRYSALIS-2 updates: amivantamab + lazertinib in EGFRm NSCLC after progression with osimertinib and chemotherapy, presented at ASCO 2022 and reported by Clinical Care Options (CCO)

Released: June 14, 2022

Adagrasib shows early encouraging activity in patients with KRAS G12C-mutant NSCLC and active, untreated CNS metastases, from Clinical Care Options (CCO) coverage of ASCO 2022

Released: June 13, 2022

Phase II NADIM II trial evaluating neoadjuvant nivolumab plus chemotherapy for resectable stage IIIA/B NSCLC, presented at ASCO 2022 and reported by Clinical Care Options (CCO)

Released: June 10, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings